Objective: To analyze the clinical features,response to therapy and prognosis of intravascular large B-cell lymphoma (IVLBCL).
Methods: The clinical data of 17 cases with IVLBCL were retrospectively reviewed,and survival analysis was conducted.
Results: The study involved 10 males and 7 females of IVLBCL with a mean age of 53 years old. The most common symptom of the disease was recurrent fever (76.5%). The lymphoma was mainly observed in bone marrow (64.7%) and was clinically determined as stage ⅣB (70.6%). Many of the patients were also diagnosed with the hemophagocytic syndrome (29.4%). R-CHOP (rituximab,cyclophosphamide,epirubicin,vindesine,prednisone) or CHOP regimen chemotherapy significantly improved the survival of the patients (P=0.000 2). Unfortunately,those patients with bone marrow involvement were prone to relapse after treatment.
Conclusion: IVLBCL is highly invasive and associated with poor prognosis. R-CHOP chemotherapy can significantly improve the prognosis.
Keywords: Clinical analysis; Hemophagocytic syndrome; Intravascular large B-cell lymphoma; Rituximab.
CopyrightCopyright© by Editorial Board of Journal of Sichuan University (Medical Science Edition).